阿昔替尼与索拉非尼一线治疗晚期肾癌的临床疗效

发布时间：2018-02-21 19:58

本文关键词： 晚期肾癌阿昔替尼索拉非尼一线治疗疗效　出处：《中国肿瘤生物治疗杂志》2017年09期 　论文类型：期刊论文

【摘要】：目的:比较阿昔替尼与索拉非尼一线治疗晚期肾癌的临床疗效,探讨分子靶向药物阿昔替尼能否作为一线治疗晚期肾癌的优选药物。方法:选取海口市人民医院肿瘤科60例晚期肾癌患者,以数字表法随机分为试验组和对照组,每组30例。实验组给予阿昔替尼,对照组给予索拉非尼治疗,比较两组患者的DCR、ORR、PFS、OS及不良反应的差异。结果:两组患者均能完成试验并进行结果评价。试验组和对照组的DCR分别为83.33%和80.00%、ORR分别为20.00%和20.00%,差异均无统计学意义(P0.05);试验组和对照组的中位PFS分别为12.8个月和10.1个月,差异有统计学意义(P0.05);中位OS分别为22.2个月和22.8个月,差异无统计学意义(P0.05)。两组患者不良反应发生率相近,差异无统计学意义(P0.05),主要表现在高血压、全身反应、手足皮肤综合征、消化道反应、肝功能损害,未见严重不良反应。结论:分子靶向药物阿昔替尼较索拉非尼一线治疗晚期肾癌更能延长患者中位PFS,两药治疗后患者的DCR、ORR、OS及不良反应相似,阿昔替尼可以作为一线治疗晚期肾癌的优选。
[Abstract]:Objective: to compare the clinical efficacy of acicitinib and sorafenib in the treatment of advanced renal cell carcinoma. Methods: 60 patients with advanced renal cell carcinoma in Department of Oncology, Haikou people's Hospital, were randomly divided into trial group and control group by digital table method. Each group (30 cases) was treated with acicatinib in the experimental group and Solafenib in the control group. Results: two groups of patients were able to complete the test and evaluate the results. The DCR of the test group and the control group were 83.33% and 80.005, respectively. There was no significant difference between the two groups (P 0.05). The median PFS of the test group and the control group were 12. 8 months and 10. 1 months, respectively. The difference was statistically significant (P 0.05), and the median OS was 22.2 months and 22.8 months, respectively. There was no significant difference in the incidence of adverse reactions between the two groups (P 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P 0.05). The main manifestations were hypertension, systemic reaction, and skin syndrome of the hand and foot. Conclusion: the molecular targeted drug oxetinib can prolong the median PFS in patients with advanced renal cell carcinoma, and the DCR-ORROS and adverse reactions of the patients after the treatment are similar, conclusion: the molecular targeted drug oxetinib can prolong the median PFS in patients with advanced renal cell carcinoma. Acetinib can be used as a first-line treatment for advanced renal cell carcinoma.
【作者单位】：海口市人民医院中医科;
【分类号】：R737.11

【相似文献】